On February 25, 2015, the Advisory Committee on Immunization Practices (ACIP) released the recommended immunization schedules for persons aged 0 through 18 years and adults 19 years and older. Both schedules, which consist of tables plus footnotes, can be found on the following pages as well as on the Centers for Disease Control and Prevention (CDC) website at http://www.cdc.gov/vaccines/schedules/hcp/index.html.

This article features updates on new pneumococcal vaccination recommendations, guidance regarding newly licensed HPV and meningococcal vaccines, and information regarding an influenza vaccine that has been recalled. It also highlights important changes and clarifications made to the ACIP 2015 immunization schedules' tables and footnotes.

**Pneumococcal Conjugate Vaccine Recommendations for Persons 65 Years and Older**

On September 19, 2014, ACIP published new recommendations for the use of 13-valent pneumococcal conjugate vaccine (PCV13) among adults 65 years and older. ACIP now recommends routine vaccination of adults 65 years and older with PCV13 if they have not received this vaccine at an earlier age. The inclusion of PCV13 in the vaccine series along with 23-valent pneumococcal polysaccharide vaccine (PPSV23) will provide broader protection against invasive pneumococcal disease (IPD) for adults in this age group.

The following are the pneumococcal vaccination recommendations for adults 65 years of age and older.

- Adults 65 years of age and older who have never received pneumococcal vaccine or their vaccination history is unknown:
  - Administer a dose of PCV13 first, then a dose of PPSV23, 6 – 12 months later. The minimal interval between doses is 8 weeks.
  - If PPSV23 cannot be administered within this time frame, administer a dose at the next health care visit.
  - Do not administer PCV13 and PPSV23 simultaneously.

- Adults 65 years and older who have previously received one or more doses of PPSV23:
  - Administer a dose of PCV13 if it has been at least one year since the last dose of PPSV23.
  - For those for whom a second dose of PPSV23 is recommended, administer the second dose 6 – 12 months after PCV13 and at least 5 years after the first dose.

- Adults 65 years and older who have previously received one dose of PPSV23 before age 65 years:
  - Administer a dose of PCV13 if it has been at least one year since the last dose of PPSV23.

Continued on page 3 >
Abbreviations: PCV13=13-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine.

* Minimum interval between sequential administration of PCV13 and PPSV23 is 8 weeks; PPSV23 can be given later than 6-12 months after PCV13 if this window is missed.

Source: Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a4.htm.
2015 IMMUNIZATION RECOMMENDATIONS from page 1

– Administer the second dose of PPSV23 at least 6 – 12 months after PCV13 and at least 5 years since the first dose.

Figure 1 provides guidance regarding CDC’s recommended intervals between doses for adults 65 years of age and older. In addition, you can download a pneumococcal vaccine timing chart for posting in your office at:

Pneumococcal vaccines are covered by most private health insurance companies. In addition, Medicare Part B covers the full cost of a second pneumococcal vaccination for Medicare enrollees. However, the second pneumococcal vaccine must be different from the first vaccine (e.g. first PCV13 then PPSV23) and should be administered no less than 11 months after the first dose. Please check with your patient’s insurance carrier to see if the vaccine is covered.

Details regarding this recommendation and other pneumococcal vaccine recommendations can be found on the CDC website at http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html.

ACIP Approves Use of New Human Papillomavirus Vaccine

On March 27, 2015, ACIP published recommendations for use of 9-valent human papillomavirus (HPV) vaccine (9vHPV; Gardasil 9, Merck and Co., Inc.). 9vHPV, along with bivalent HPV (2vHPV; Cervarix, GlaxoSmithKline) and quadrivalent HPV (4vHPV; Gardasil, Merck and Co., Inc.) vaccines can be used for routine vaccination of adolescents 11 through 12 years of age. HPV vaccine can also be administered to children as young as 9 years of age. Note: Only 4vHPV and 9vHPV are licensed for use in males and females; 2vHPV is not licensed for use in males.

The 9vHPV is similar to the quadrivalent HPV vaccine in that it contains four of the same HPV strains, 6, 11, 16, and 18. It also contains an additional five strains (31, 33, 45, 52, and 58) which account for 15% of cervical cancers, resulting in approximately 80% total coverage for the HPV strains that have been associated with cervical cancer. It can also prevent genital warts and other types of cancer, including oral cancer.

All three products, 9vHPV, 4vHPV, and 2vHPV, can be used for catch-up vaccination for females aged 13 through 26 years. Only 9vHPV and 4vHPV should be used for males aged 13 through 21 years who have not been previously vaccinated. In addition, these two vaccine products can be used for men who have sex with men (MSM) and immunocompromised men (including those with HIV infection) through 26 years of age if not previously vaccinated.

Health care providers who do not know the previous HPV vaccination history or who are transitioning to 9vHPV can use any HPV vaccine product to continue or complete the series for females. Only 9vHPV and 4vHPV may be used to continue or complete the series for males.

More information regarding 9vHPV, including safety and efficacy data, is available on the CDC website at http://www.cdc.gov/mmwr/pdf/wk/mm6411.pdf.

New Meningococcal B Vaccines

Two meningococcal B serogroup vaccines were licensed in 2014: Trumenba (Pfizer) and Bexsero (Novartis). Both vaccines are licensed for persons age 10 through 25 years. However, ACIP recommends that the vaccines only be used for persons in this age group with complement component deficiencies, functional or anatomic asplenia; microbiologists routinely exposed to N. meningitidis; and persons exposed to meningococcal B during outbreaks. The ACIP guidelines for meningococcal B vaccines are expected to be published later this year.

Important Vaccine Recall

GSK is voluntarily recalling all remaining lots of 2014-2015 FLULAVAL® QUADRIVALENT Thimerosal-Free Pre-Filled Syringes (PFS). As part of stability testing, GSK observed loss of potency below the minimum specification prior to product expiration for the B strains included in the vaccine. The lots are being recalled due to the potential for reduced efficacy offered by the vaccine and not as a result of any identified safety concern. Additional information regarding the recall is posted at www.cdc.gov/flu/news/gsk-flu-vaccine-recall.htm.

2015 Recommended Immunization Schedule for Person 0 through 18 Years of Age

There are no new vaccine recommendations for this age group. However, Figure 2 (table) and Figure 4 (footnotes) have been revised to clarify recommendations for some vaccines. The most significant modifications are noted below.

• Diphtheria, Tetanus, and acellular Pertussis (DTaP) – CDC footnote #3 on Figure 4 now indicates that a fourth dose DTaP vaccine that is administered 4 months or more after the third dose, at an appropriate age, is considered a valid dose, and should not be repeated.

• Pneumococcal Conjugate Vaccine – CDC footnote #6 on Figure 4 was updated to clarify recommendations for vaccinating children 2 through 5 years of age with certain high-risk conditions. These providers should administer:
  – 1 dose of PCV13 if the child previously received any incomplete schedule of 3 doses of PCV (PCV7 and/or PCV13).

continued on page 4 >
2015 Immunization Schedules for Health Care Professionals and Patients

- 2 doses of PCV13 at least 8 weeks apart if the child is unvaccinated or previously received any incomplete schedule of fewer than 3 doses of PCV (PCV7 and/or PCV13).

Although these are not new recommendations, providers are also reminded to administer:
- 1 supplemental dose of PCV13 at least 8 weeks apart if the child previously received 4 doses of PCV7 or other age-appropriate complete PCV7 series.
- 1 dose of PPSV23 at least 8 weeks after the most recent PCV13 dose if the child has no previous history of PPSV23.

• **Influenza** – The table was modified to highlight current recommendations for influenza vaccinations. The gold bar, which denotes a routine vaccination recommendation, for live attenuated influenza vaccine (LAIV) or inactivated influenza vaccine (IIV) highlights the recommendation for 1 or 2 doses for children 2 through 8 years of age (midpoint of column for 7–10 years). An additional gold bar was added to signify that 1 dose is recommended annually for children and adolescents 9 through 18 years of age.

CDC footnote #8 on Figure 4 was updated to reflect revised contraindications for LAIV. LAIV should not be administered to the following persons: 1) persons who have experienced severe allergic reactions to LAIV, any of its components, or to a previous dose of any other influenza vaccine; 2) children aged 2 through 17 years receiving aspirin or aspirin-containing products; 3) persons who are allergic to eggs; 4) pregnant women; 5) immunosuppressed persons; 6) children aged 2 through 4 years who have asthma or had wheezing in the past 12 months; and 7) persons who have taken influenza antiviral medications in the previous 48 hours. All other contraindications and precautions for the use of LAIV are available at [http://www.cdc.gov/mmwr/pdf/wk/mm6332.pdf](http://www.cdc.gov/mmwr/pdf/wk/mm6332.pdf).

• **Measles, Mumps and Rubella (MMR)** – A purple bar, which denotes a vaccination recommendation for high risk groups, was added to the table for measles-mumps-rubella (MMR) vaccine indicating that children aged 6 through 11 months should be vaccinated prior to traveling internationally or living abroad. Please remember that any dose of MMR given before 12 months of age must be repeated when the child is 12 months of age because some infants do not respond to the vaccine at the earlier age.

• **Meningococcal Conjugate Vaccine** – CDC footnote #13 on Figure 4 was revised to clarify the recommendations for use of MenACWY-CRM (Menveo), MenACWY-D (Menactra), and Hib-MenCY-TT (Men Hibrix) in children aged 2 months and older with anatomic or functional asplenia, or with persistent complement deficiencies.

**Catch-Up Immunization Schedule for Persons Aged 4 Months through 18 Years**

The following changes were made to Figure 3, the 2015 catch-up immunization schedule:

- *Haemophilus influenzae* type b (Hib) conjugate vaccine; pneumococcal conjugate vaccine (PCV); tetanus, diphtheria, and acellular pertussis vaccine (Tdap); and varicella vaccine catch-up schedules were updated to provide more clarity.

- Minimum ages were noted as "not-applicable" for children aged 7 years and older for hepatitis A and B, polio, meningococcal, MMR, and varicella vaccines.

CDC has also developed "job-aids" with detailed scenarios by age group and previous doses of vaccine received for DTap, Hib, and pneumococcal conjugate vaccines. These materials are available at [http://www.cdc.gov/vaccines/schedules/hcp/schedule-app.html](http://www.cdc.gov/vaccines/schedules/hcp/schedule-app.html).

**2015 Immunization Schedules for Health Care Professionals and Patients**

- Birth – 18 Years & Catch-up Immunization Schedules

- Adult Immunization Schedule
  [http://www.cdc.gov/vaccines/schedules/hcp/adult.html](http://www.cdc.gov/vaccines/schedules/hcp/adult.html)

- CDC Vaccine Schedules App for Clinicians
  [http://www.cdc.gov/vaccines/schedules/hcp/schedule-app.html](http://www.cdc.gov/vaccines/schedules/hcp/schedule-app.html)

- Easy-to-Read Immunization Schedules for Patients
  [http://www.cdc.gov/vaccines/schedules/easy-to-read/index.html](http://www.cdc.gov/vaccines/schedules/easy-to-read/index.html)

- New and Updated Vaccine Information Statements including HPV, Hib, PPSV, and Rotavirus
  [http://www.immunize.org/vis/](http://www.immunize.org/vis/)

**continued on page 5 >**
can assist health care providers interpret the catch-up immunization schedule. The job-aids are available on the CDC website at http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html.

**Recommended Immunization Schedule for Adults 19 Years and Older**

ACIP updated Figure 5, the adult immunization schedule with the following important changes.

- **Influenza Vaccine** – CDC footnote #2 on Figure 6 has been updated to indicate that adults aged 18 years or older can receive recombinant influenza vaccine (RIV). Previously, the footnote specified that this vaccine could be received only for adults aged 18 through 49 years of age. Of note, the upper age limit for LAIV remains 49 years. In addition, influenza antiviral use within the last 48 hours is now a contraindication to influenza vaccination. Meanwhile, the following are no longer listed as contraindications to vaccination, but are considered precautions: asthma and chronic lung diseases; cardiovascular, renal, and hepatic diseases; diabetes and other conditions. These changes are reflected in Table 1 “Contraindications and Precautions to Commonly Used Vaccines in Adults”

- **Pneumococcal vaccine** – The adult table and footnotes have been revised to include the new PCV13 recommendation for adults aged 65 years and older, as discussed in the Pneumococcal update section on page 1. CDC footnote #8 on Figure 6 has also been revised to provide clearer guidance regarding PCV13 and PPSV23 vaccination, including age indications and recommended intervals.

**Conclusion**

Vaccines protect infants, children, and adults against serious communicable diseases, if administered per the CDC guidelines. Please share the updated schedules and footnotes with all health care personnel in your clinic, especially those staff who provide immunization services. Also, replace copies of the 2014 schedule posted in your clinic with the new 2015 version. For more information about immunizations and online and in-person immunization training sessions, please visit http://publichealth.lacounty.gov/ip/trainconf.htm.

March marked National Colorectal Cancer Awareness Month. Hundreds of health organizations signed the 80% by 2018 pledge, including the Los Angeles County Department of Public Health, working together to increase the nation’s colon cancer testing rate to 80% by the year 2018.

80% by 2018 is an initiative of the National Colorectal Cancer Roundtable, which was co-founded by the American Cancer Society and the Centers for Disease Control and Prevention. Colon cancer is the second leading cause of cancer death in the United States when men and women are combined. Screening offers an opportunity for colon cancer prevention and early detection, but about 1 in 3 L.A. County adults (50+) are not getting tested as recommended.

As a health care provider, your recommendation is the most influential factor in determining whether a patient is screened for colon cancer. Find more information and tools for your practice at www.cancer.org/colonmd
Figure 2. Immunization Schedule: Ages 0 through 18 Years- United States, 2015.

(FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]).

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Birth</th>
<th>1 mo</th>
<th>2 mos</th>
<th>4 mos</th>
<th>6 mos</th>
<th>9 mos</th>
<th>12 mos</th>
<th>15 mos</th>
<th>18 mos</th>
<th>19–23 mos</th>
<th>2-3 yrs</th>
<th>4-6 yrs</th>
<th>7-10 yrs</th>
<th>11-12 yrs</th>
<th>13-15 yrs</th>
<th>16–18 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B (HepB)</td>
<td>1st dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus (RV) RV1 (2-dose series); RVS (3-dose series)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, &amp; acellular pertussis (DTaP; &lt;7 yrs)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, &amp; acellular pertussis (Tdap; ≥7 yrs)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV13)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus (IPV; &lt;18 yrs)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza A/B/IV (LAV): 2 doses for some: See footnote 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination (LAV only) 1 or 2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella (VAR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination (LAV or IV) 1 or 2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination (LAV or IV) 1 dose only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus 2 (HPV2; females only; HPV4: males and females)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination (LAV only) 1 or 2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal (Hib-MenCY ≥ 6 weeks; MenACY-D ≥9 mos; MenACY-CRM ≥ 2 mos)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination (LAV only) 1 or 2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This schedule includes recommendations in effect as of January 1, 2015. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at http://www.cdc.gov/vaccines/hcp/acip-recs/index.html. Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online (http://www.vaers.hhs.gov) or by telephone (800-822-7967). Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for vaccination, is available from CDC online (http://www.cdc.gov/vaccines/recs/vac-admin/contraindications.htm) or by telephone (800-CDC-INFO [800-232-4636]).

This schedule is approved by the Advisory Committee on Immunization Practices (http://www.cdc.gov/vaccines/acip), the American Academy of Pediatrics (http://www.aap.org), the American Academy of Family Physicians (http://www.aafp.org), and the American College of Obstetricians and Gynecologists (http://www.acog.org).

NOTE: The above recommendations must be read along with the footnotes of this schedule.
**Figure 2. Catch-up Immunization Schedule for Persons Aged 4 Months through 18 Years Who Start Late or Who Are More Than 1 Month Behind — United States, 2015.**

The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age. Always use this table in conjunction with Figure 1 and the footnotes that follow.

### Children Aged 4 Months through 6 Years

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Minimum Interval Between Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose 1 to Dose 2</td>
<td>Dose 2 to Dose 3</td>
</tr>
<tr>
<td>Hepatitis B&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Birth</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Rotavirus&lt;sup&gt;2&lt;/sup&gt;</td>
<td>6 weeks</td>
<td>4 weeks&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diphtheria, tetanus, and acellular pertussis&lt;sup&gt;3&lt;/sup&gt;</td>
<td>6 weeks</td>
<td>4 weeks&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

### Children Aged 7 through 18 Years

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Minimum Interval Between Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose 1 to Dose 2</td>
<td>Dose 2 to Dose 3</td>
</tr>
<tr>
<td>Tetanus, diphtheria, tetanus, diphtheria, and acellular pertussis&lt;sup&gt;4&lt;/sup&gt;</td>
<td>7 years&lt;sup&gt;4&lt;/sup&gt;</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Human papillomavirus&lt;sup&gt;5&lt;/sup&gt;</td>
<td>9 years&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Routine dosing intervals are recommended&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hepatitis A&lt;sup&gt;6&lt;/sup&gt;</td>
<td>N/A</td>
<td>6 months&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hepatitis B&lt;sup&gt;1&lt;/sup&gt;</td>
<td>N/A</td>
<td>8 weeks&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Inactivated poliovirus&lt;sup&gt;7&lt;/sup&gt;</td>
<td>N/A</td>
<td>4 weeks&lt;sup&gt;7&lt;/sup&gt;</td>
</tr>
<tr>
<td>Meningococcal&lt;sup&gt;11&lt;/sup&gt;</td>
<td>N/A</td>
<td>8 weeks&lt;sup&gt;11&lt;/sup&gt;</td>
</tr>
<tr>
<td>Measles, mumps, rubella&lt;sup&gt;9&lt;/sup&gt;</td>
<td>N/A</td>
<td>6 months&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td>Varicella&lt;sup&gt;10&lt;/sup&gt;</td>
<td>N/A</td>
<td>6 months&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

**NOTE:** The above recommendations must be read along with the footnotes of this schedule.
**Additional information**

- For contraindications and precautions to use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the relevant ACIP statement available online at [http://www.cdc.gov/vaccines/hcp/acip-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/index.html).
- For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
- Vaccine doses administered 4 days or less before the minimum interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum interval or minimum age should not be counted as valid doses and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see *MMWR, General Recommendations on Immunization and Reports* / Vol. 60 / No. 2; Table 1. *Recommended and minimum ages and intervals between vaccine doses available online at [http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf](http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf).*

### 1. Hepatitis B (HepB) vaccine. (Minimum age: birth)

**Routine vaccination:**
- **At birth:**
  - Administer monovalent HepB vaccine to all newborns before hospital discharge.
  - For infants born to hepatitis B surface antigen (HBsAg)-positive mothers, administer HepB vaccine and 0.5 mL of hepatitis B immune globulin (HBIg) within 12 hours of birth. These infants should be tested for HBsAg and antibody to HBsAg (anti-HBs) 1 to 2 months after completion of the HepB series at age 9 through 18 months (preferably at the next well-child visit).
  - If mother’s HBsAg status is unknown, within 12 hours of birth administer HepB vaccine regardless of birth weight. For infants weighing less than 2,000 grams, administer HBIg in addition to HepB vaccine within 12 hours of birth. Determine mother’s HBsAg status as soon as possible and, if mother is HBsAg-positive, also administer HBIg for infants weighing 2,000 grams or more as soon as possible, but no later than age 7 days.

**Doses following the birth dose:**
- The second dose should be administered at age 1 or 2 months. Monovalent HepB vaccine should be used for doses administered before age 6 weeks.
- Infants who did not receive a birth dose should receive 3 doses of a HepB-containing vaccine on a schedule of 0, 1 to 2 months, and 6 months starting as soon as feasible. See Figure 2.
- Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks), administer the third dose at least 8 weeks after the second dose AND at least 16 weeks after the first dose. The final (third or fourth) dose in the HepB vaccine series should be administered no earlier than age 24 weeks.
- Administration of a total of 4 doses of HepB vaccine is permitted when a combination vaccine containing HepB is administered after the birth dose.

**Catch-up vaccination:**
- Unvaccinated persons should complete a 3-dose series.
- A 2-dose series (doses separated by at least 4 months) of adult formulation Recombivax HB is licensed for use in children aged 11 through 15 years.
- For other catch-up guidance, see Figure 2.

### 2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both RV1 [Rotarix] and RV5 [RotaTeq])

**Routine vaccination:**
- Administer a series of RV vaccine to all infants as follows:
  1. If Rotarix is used, administer a 2-dose series at 2 and 4 months of age.
  2. If RotaTeq is used, administer a 3-dose series at ages 2, 4, and 6 months.
  3. If any dose in the series was RotaTeq or vaccine product is unknown for any dose in the series, a total of 3 doses of RV vaccine should be administered.

**Catch-up vaccination:**
- The maximum age for the first dose in the series is 14 weeks, 6 days; vaccination should not be initiated for infants aged 15 weeks, 0 days or older.
- The maximum age for the final dose in the series is 8 months, 0 days.
- For other catch-up guidance, see Figure 2.

### 3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. (Minimum age: 6 weeks. Exception: DTaP-IPV [Kinrix]: 4 years)

**Routine vaccination:**
- Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15 through 18 months, and 4 through 6 years. The fourth dose may be administered as early as age 12 months, provided at least 6 months have elapsed since the third dose. However, the fourth dose of DTaP need not be repeated if it was administered at least 4 months after the third dose of DTaP.

**Catch-up vaccination:**
- The fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older.
- For other catch-up guidance, see Figure 2.

### 4. Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine. (Minimum age: 10 years for both Boostrix and Adacel)

**Routine vaccination:**
- Administer 1 dose of Tdap vaccine to all adolescents aged 11 through 12 years.
- Tdap may be administered regardless of the interval since the last tetanus and diphtheria toxoid-containing vaccine.
- Administer 1 dose of Tdap vaccine to pregnant adolescents during each pregnancy (preferred during 27 through 36 weeks’ gestation) regardless of time since prior Td or Tdap vaccination.

**Catch-up vaccination:**
- Persons aged 7 years and older who are not fully immunized with DTaP vaccine should receive Tdap vaccine as 1 dose (preferably the first) in the catch-up series; if additional doses are needed, use Td vaccine. For children 7 through 10 years who receive a dose of Tdap as part of the catch-up series,
an adolescent Tdap vaccine dose at age 11 through 12 years should NOT be administered. Td should be administered instead 10 years after the Tdap dose.

- Persons aged 11 through 18 years who have not received Tdap vaccine should receive a dose followed by tetanus and diphtheria toxoid (Td) booster doses every 10 years thereafter.

- Inadvertent doses of DTaP vaccine:
  - If administered inadvertently to a child aged 7 through 10 years may count as part of the catch-up series. This dose may count as the adolescent Tdap dose, or the child can later receive a Tdap booster dose at age 11 through 12 years.
  - If administered inadvertently to an adolescent aged 11 through 18 years, the dose should be counted as the adolescent Tdap booster.

- For other catch-up guidance, see Figure 2.

5. *Haemophilus influenzae* type b (Hib) conjugate vaccine. (Minimum age: 6 weeks for PRP-T [ACTHIB, DTaP-IPV/Hib (Pentacel) and Hib-MenCY (MenHibrix)], PRP-OMP [PedvaxHIB or COMVAX], 12 months for PRP-T [Hiberix])

Routine vaccination:
- Administer a 2- or 3-dose Hib vaccine primary series and a booster dose (dose 3 or 4 depending on vaccine used in primary series) at age 12 through 15 months to complete a full Hib vaccine series.
- The primary series with ActHIB, MenHibrix, or Pentacel consists of 3 doses and should be administered at 2, 4, and 6 months of age. The primary series with PedvaxHib or COMVAX consists of 2 doses and should be administered at 2 and 4 months of age, a dose at age 6 months is not indicated.
- One booster dose (dose 3 or 4 depending on vaccine used in primary series) of any Hib vaccine should be administered at age 12 through 15 months. An exception is Hiberix vaccine. Hiberix should only be used for the booster (final) dose in children aged 12 months through 4 years who have received at least 1 prior dose of Hib-containing vaccine.
- For recommendations on the use of MenHibrix in patients at increased risk for meningococcal disease, please refer to the meningococcal vaccine footnotes and also to MMWR February 28, 2014 / 63(RR01);1-13, available at http://www.cdc.gov/mmwr/IR/rr6301.pdf.

Catch-up vaccination:
- If dose 1 was administered at ages 12 through 14 months, administer a second (final) dose at least 8 weeks after dose 1, regardless of Hib vaccine used in the primary series.
- If both doses were PRP-OMP (PedvaxHib or COMVAX), and were administered before the first birthday, the third (and final) dose should be administered at age 12 through 59 months and at least 8 weeks after the second dose.
- If the first dose was administered at age 7 through 11 months, administer the second dose at least 4 weeks later and a third (and final) dose at age 12 through 15 months or 8 weeks after second dose, whichever is later.
- If first dose is administered before the first birthday and second dose administered at younger than 15 months, a third (and final) dose should be given 8 weeks later.
- For unvaccinated children aged 15 months or older, administer only 1 dose.
- For other catch-up guidance, see Figure 2. For catch-up guidance related to MenHibrix, please see the meningococcal vaccine footnotes and also MMWR February 28, 2014 / 63(RR01);1-13, available at http://www.cdc.gov/mmwr/IR/rr6301.pdf.

Vaccination of persons with high-risk conditions:
- Children aged 12 through 59 months who are at increased risk for Hib disease, including chemotherapy recipients and those with anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV) infection, immunoglobulin deficiency, or early component complement deficiency, who have received either no doses or only 1 dose of Hib vaccine before 12 months of age, should receive 2 additional doses of Hib vaccine 8 weeks apart; children who received 2 or more doses of Hib vaccine before 12 months of age should receive 1 additional dose.
- For patients younger than 5 years of age undergoing chemotherapy or radiation treatment who received a Hib vaccine dose(s) within 14 days of starting therapy or during therapy, repeat the dose(s) at least 3 months following therapy completion.
- Recipients of hematopoietic stem cell transplant (HSCT) should be revaccinated with a 3-dose regimen of Hib vaccine starting 6 to 12 months after successful transplant, regardless of vaccination history; doses should be administered at least 4 weeks apart.
- A single dose of any Hib-containing vaccine should be administered to unimmunized* children and adolescents 15 months of age and older undergoing an elective splenectomy; if possible, vaccine should be administered at least 14 days before procedure.
- Hib vaccine is not routinely recommended for patients 5 years or older. However, 1 dose of Hib vaccine should be administered to unimmunized* persons aged 5 years or older who have anatomic or functional asplenia (including sickle cell disease) and unvaccinated persons 5 through 18 years of age with human immunodeficiency virus (HIV) infection.

* Patients who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after 14 months of age are considered unimmunized.

6. Pneumococcal vaccines. (Minimum age: 6 weeks for PCV13, 2 years for PPSV23)

Routine vaccination with PCV13:
- Administer a 4-dose series of PCV13 vaccine at ages 2, 4, and 6 months and at age 12 through 15 months.
- For children aged 14 through 59 months who have received an age-appropriate series of 7-valent PCV (PCV7), administer a single supplemental dose of 13-valent PCV (PCV13).

Catch-up vaccination with PCV13:
- Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely vaccinated for their age.
- For other catch-up guidance, see Figure 2.

Vaccination of persons with high-risk conditions with PCV13 and PPSV23:
- All recommended PCV13 doses should be administered prior to PPSV23 vaccination if possible.
- For children 2 through 5 years of age with any of the following conditions: chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy); diabetes mellitus; cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin’s disease; solid organ transplantation; or congenital immunodeficiency:
  1. Administer 1 dose of PCV13 if any incomplete schedule of 3 doses of PCV (PCV7 and/or PCV13) were received previously.
  2. Administer 2 doses of PCV13 at least 8 weeks apart if unvaccinated or any incomplete schedule of fewer than 3 doses of PCV (PCV7 and/or PCV13) were received previously.
  3. Administer 1 supplemental dose of PCV13 if 4 doses of PCV7 or other age-appropriate complete PCV7 series was received previously.
  4. The minimum interval between doses of PCV (PCV7 or PCV13) is 8 weeks.
  5. For children with no history of PPSV23 vaccination, administer PPSV23 at least 8 weeks after the most recent dose of PCV13.

- For children aged 6 through 18 years who have cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated
with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin’s disease; generalized malignancy; solid organ transplantation; or multiple myeloma:
1. If neither PCV13 nor PPSV23 has been received previously, administer 1 dose of PCV13 now and 1 dose of PPSV23 at least 8 weeks later.
2. If PCV13 has been received previously but PPSV23 has not, administer 1 dose of PPSV23 at least 8 weeks after the most recent dose of PCV13.
3. If PPSV23 has been received but PCV13 has not, administer 1 dose of PCV13 at least 8 weeks after the most recent dose of PPSV23.
• For children aged 6 through 18 years with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure), chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus, alcoholism, or chronic liver disease, who have not received PPSV23, administer 1 dose of PPSV23. If PCV13 has been received previously, then PPSV23 should be administered at least 8 weeks after any prior PCV13 dose.
• A single revaccination with PPSV23 should be administered 5 years after the first dose to children with sickle cell disease or other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin’s disease; generalized malignancy; solid organ transplantation; or multiple myeloma.

7. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
Routine vaccination:
• Administer a 4-dose series of IPV at ages 2, 4, 6 through 18 months, and 4 through 6 years. The final dose in the series should be administered on or after the fourth birthday and at least 6 months after the previous dose.
Catch-up vaccination:
• In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk of imminent exposure to circulating poliovirus (i.e., travel to a polio-endemic region or during an outbreak).
• If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 through 6 years and at least 6 months after the previous dose.
• A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.
• If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age. IPV is not routinely recommended for U.S. residents aged 18 years or older.
• For other catch-up guidance, see Figure 2.

8. Influenza vaccines. (Minimum age: 6 months for inactivated influenza vaccine [IIV], 2 years for live, attenuated influenza vaccine [LAIV])
Routine vaccination:
• Administer influenza vaccine annually to all children beginning at age 6 months. For most healthy, nonpregnant persons aged 2 through 49 years, either LAIV or IIV may be used. However, LAIV should NOT be administered to some persons, including 1) persons who have experienced severe allergic reactions to LAIV, any of its components, or to a previous dose of any other influenza vaccine; 2) children 2 through 17 years receiving aspirin or aspirin-containing products; 3) persons who are allergic to eggs; 4) pregnant women; 5) immunosuppressed persons; 6) children 2 through 4 years of age with asthma or who had wheezing in the past 12 months; or 7) persons who have taken influenza antiviral medications in the previous 48 hours. For all other contraindications and precautions to use of LAIV, see MMWR May 15, 2014 / 63(19):586-598 [40 pages] available at http://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf.

For children aged 6 months through 8 years:
• For the 2014-15 season, administer 2 doses (separated by at least 4 weeks) to children who are receiving influenza vaccine for the first time. Some children in this age group who have been vaccinated previously will also need 2 doses. For additional guidance, follow dosing guidelines in the 2014-15 ACIP influenza vaccine recommendations, MMWR August 15, 2014 / 63(32):691-697 [40 pages] available at http://www.cdc.gov/mmwr/pdf/wk/mm6332.pdf.
• For the 2015–16 season, follow dosing guidelines in the 2015 ACIP influenza vaccine recommendations.

For persons aged 9 years and older:
• Administer 1 dose.

9. Measles, mumps, and rubella (MMR) vaccine. (Minimum age: 12 months for routine vaccination)
Routine vaccination:
• Administer a 2-dose series of MMR vaccine at ages 12 through 15 months and 4 through 6 years. The second dose may be administered before age 4 years, provided at least 4 weeks have elapsed since the first dose.
• Administer 1 dose of MMR vaccine to infants aged 6 through 11 months before departure from the United States for international travel. These children should be revaccinated with 2 doses of MMR vaccine, the first at age 12 through 15 months (12 months if the child remains in an area where disease risk is high), and the second dose at least 4 weeks later.
• Administer 2 doses of MMR vaccine to children aged 12 months and older before departure from the United States for international travel. The first dose should be administered on or after age 12 months and the second dose at least 4 weeks later.
Catch-up vaccination:
• Ensure that all school-aged children and adolescents have had 2 doses of MMR vaccine; the minimum interval between the 2 doses is 4 weeks.

10. Varicella (VAR) vaccine. (Minimum age: 12 months)
Routine vaccination:
• Administer a 2-dose series of VAR vaccine at ages 12 through 15 months and 4 through 6 years. The second dose may be administered before age 4 years, provided at least 3 months have elapsed since the first dose. If the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid.
Catch-up vaccination:
• Ensure that all persons aged 7 through 18 years without evidence of immunity (see MMWR 2007 / 56 [No. RR-4], available at http://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 doses of varicella vaccine. For children aged 7 through 12 years, the recommended minimum interval between doses is 3 months (if the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid); for persons aged 13 years and older, the minimum interval between doses is 4 weeks.

11. Hepatitis A (HepA) vaccine. (Minimum age: 12 months)
Routine vaccination:
• Initiate the 2-dose HepA vaccine series at 12 through 23 months; separate the 2 doses by 6 to 18 months.
• Children who have received 1 dose of HepA vaccine before age 24 months should receive a second dose 6 to 18 months after the first dose.
• For any person aged 2 years and older who has not already received the HepA vaccine series, 2 doses of HepA vaccine separated by 6 to 18 months may be administered if immunity against hepatitis A virus infection is desired.
Catch-up vaccination:
• The minimum interval between the two doses is 6 months.
Special populations:
• Administer 2 doses of HepA vaccine at least 6 months apart to previously
unvaccinated persons who live in areas where vaccination programs target older children, or who are at increased risk for infection. This includes persons traveling to or working in countries that have high or intermediate endemicity of infection; men having sex with men; users of injection and non-injection illicit drugs; persons who work with HAV-infected primates or with HAV in a research laboratory; persons with clotting-factor disorders; persons with chronic liver disease; and persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity. The first dose should be administered as soon as the adoption is planned, ideally 2 or more weeks before the arrival of the adoptee.

12. Human papillomavirus (HPV) vaccines. (Minimum age: 9 years for HPV2 [Cervarix] and HPV4 [Gardasil])

Routine vaccination:
- Administer a 3-dose series of HPV vaccine on a schedule of 0, 1-2, and 6 months to all adolescents aged 11 through 12 years. Either HPV4 or HPV2 may be used for females, and only HPV4 may be used for males.
- The vaccine series may be started at age 9 years.
- Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks); administer the third dose 24 weeks after the first dose and 16 weeks after the second dose (minimum interval of 12 weeks).

Catch-up vaccination:
- Administer the vaccine series to females (either HPV2 or HPV4) and males (HPV4) at age 13 through 18 years if not previously vaccinated.
- Use recommended routine dosing intervals (see Routine vaccination above) for vaccine series catch-up.

13. Meningococcal conjugate vaccines. (Minimum age: 6 weeks for Hib-MenCY [MenHibrix], 9 months for MenACWY-D [Menactra], 2 months for MenACWY-CRM [Menveo])

Routine vaccination:
- Administer a single dose of Menactra or Menveo vaccine at age 11 through 12 years, with a booster dose at age 16 years.
- Adolescents aged 11 through 18 years with human immunodeficiency virus (HIV) infection should receive a 2-dose primary series of Menactra or Menveo with at least 8 weeks between doses.
- For children aged 2 months through 18 years with high-risk conditions, see below.

Catch-up vaccination:
- Administer Menactra or Menveo vaccine at age 13 through 18 years if not previously vaccinated.
- If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 16 through 18 years with a minimum interval of at least 8 weeks between doses.
- If the first dose is administered at age 16 years or older, a booster dose is not needed.
- For other catch-up guidance, see Figure 2.

Vaccination of persons with high-risk conditions and other persons at increased risk of disease:
- Children with anatomic or functional asplenia (including sickle cell disease): 1. Menveo
- Children who initiate vaccination at 8 weeks through 6 months: Administer doses at 2, 4, 6, and 12 months of age.
- Unvaccinated children 7 through 23 months: Administer 2 doses, with the second dose at least 12 weeks after the first dose AND after the first birthday.
- Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart.

2. MenHibrix
- Children 6 weeks through 18 months: Administer doses at 2, 4, 6, and 12 through 15 months of age.
- If the first dose of MenHibrix is given at or after 12 months of age, a total of 2 doses should be given at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease.

3. Menactra
- Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart. If Menactra is administered to a child with asplenia (including sickle cell disease), do not administer Menactra until 2 years of age and at least 4 weeks after the completion of all PCV13 doses.
- Children with persistent complement component deficiency:
  1. Menveo
- Children who initiate vaccination at 8 weeks through 6 months: Administer doses at 2, 4, 6, and 12 months of age.
- Unvaccinated children 7 through 23 months: Administer 2 doses, with the second dose at least 12 weeks after the first dose AND after the first birthday.
- Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart.

2. MenHibrix
- Children 6 weeks through 18 months: Administer doses at 2, 4, 6, and 12 through 15 months of age.
- If the first dose of MenHibrix is given at or after 12 months of age, a total of 2 doses should be given at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease.

3. Menactra
- Children 9 through 23 months: Administer 2 primary doses at least 12 weeks apart.
- Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart.
- For children who travel to or reside in countries in which meningococcal disease is hyperendemic or epidemic, including countries in the African meningitis belt or the Hajj, administer an age-appropriate formulation and series of Menactra or Menveo for protection against serogroups A and W meningococcal disease. Prior receipt of MenHibrix is not sufficient for children traveling to the meningitis belt or the Hajj because it does not contain serogroups A or W.
- For children at risk during a community outbreak attributable to a vaccine serogroup, administer or complete an age- and formulation-appropriate series of MenHibrix, Menactra, or Menveo.
- For booster doses among persons with high-risk conditions, refer to MMWR 2013 / 62(RR02);1-22, available at [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm).

For other catch-up recommendations for these persons, and complete information on use of meningococcal vaccines, including guidance related to vaccination of persons at increased risk of infection, see MMWR March 22, 2013 / 62(RR02);1-22, available at [http://www.cdc.gov/mmwr/pdf/rr/rr6202a1.pdf](http://www.cdc.gov/mmwr/pdf/rr/rr6202a1.pdf).
Figure 1. Recommended adult immunization schedule, by vaccine and age group

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>AGE GROUP</th>
<th>19-21 years</th>
<th>22-26 years</th>
<th>27-49 years</th>
<th>50-59 years</th>
<th>60-64 years</th>
<th>≥ 65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Influenza</strong></td>
<td>1 dose annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tetanus, diphtheria, pertussis (Td/Tdap)</strong></td>
<td></td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Varicella</strong></td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Human papillomavirus (HPV) Female</strong></td>
<td></td>
<td>1 or 2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Human papillomavirus (HPV) Male</strong></td>
<td></td>
<td>1 or 3 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Zoster</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Measles, mumps, rubella (MMR)</strong></td>
<td></td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pneumococcal 13-valent conjugate (PCV13)</strong></td>
<td></td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pneumococcal polysaccharide (PPSV23)</strong></td>
<td></td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Meningococcal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis A</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis B</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Covered by the Vaccine Injury Compensation Program

For all persons in this category who meet the age requirements and who lack documentation of vaccination or have no evidence of previous infection; zoster vaccine recommended regardless of prior episode of zoster.

Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indication).

No recommendation.

Figure 2. Vaccines that might be indicated for adults based on medical and other indications

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>INDICATION</th>
<th>Pregnancy</th>
<th>Immuno-compromising conditions (excluding human immunodeficiency virus (HIV))</th>
<th>HIV infection</th>
<th>Men who have sex with men (MSM)</th>
<th>Kidney failure, end-stage renal disease, receipt of hemodialysis</th>
<th>Heart disease, chronic lung disease, chronic alacrima</th>
<th>Asplenia (including elective splenectomy and persistent complement component deficiencies)</th>
<th>Chronic liver disease</th>
<th>Diabetes</th>
<th>Healthcare personnel</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Influenza</strong></td>
<td>1 dose IV annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tetanus, diphtheria, pertussis (Td/Tdap)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Varicella</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Human papillomavirus (HPV) Female</strong></td>
<td></td>
<td>3 doses through age 26 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Human papillomavirus (HPV) Male</strong></td>
<td></td>
<td>3 doses through age 26 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Zoster</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Measles, mumps, rubella (MMR)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pneumococcal 13-valent conjugate (PCV13)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pneumococcal polysaccharide (PPSV23)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Meningococcal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis A</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis B</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hemophilus influenzae type b (Hib)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Covered by the Vaccine Injury Compensation Program

Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at www.vaers.hhs.gov or by telephone, 800-822-7967.

Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination is also available at www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-232-4636 in English and Spanish, 8:00 a.m. - 8:00 p.m. Eastern Time, Monday - Friday, excluding holidays.

These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly recommended for adults ages 19 years and older, as of February 1, 2015. For all vaccines being recommended on the Adult Immunization Schedule, a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine’s other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers’ package inserts and the complete statements from the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/hcp/acip-recs/index.html). Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
1. Additional information

- Additional guidance for the use of the vaccines described in this supplement is available at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
- Information on vaccination recommendations when vaccination status is unknown and other general immunization information can be found in the General Recommendations on Immunization at www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
- Information on travel vaccine requirements and recommendations (e.g., for hepatitis A and B, meningococcal, and other vaccines) is available at www.cdc.gov/travel/destinations/list.
- Additional information and resources regarding vaccination of pregnant women can be found at www.cdc.gov/vaccines/adults/pregnant.html.

2. Influenza vaccination

- Annual vaccination against influenza is recommended for all persons aged 6 months or older.
- Persons aged 6 months or older, including pregnant women and persons with hiv-only allergies to eggs can receive the inactivated influenza vaccine (IIV). An age-appropriate IIV formulation should be used.
- Adults aged 18 years or older can receive the recombinant influenza vaccine (RIV) (FluBlok). RIV does not contain any egg protein and can be given to ageappropriate persons with egg allergy of any severity.
- Healthy, nonpregnant persons aged 2 to 49 years without high-risk medical conditions can receive either intranasally administered live, attenuated influenza vaccine (LAIV) (Flumist) or IIV.
- Health care personnel who care for severely immunocompromised persons who require care in a protected environment should receive IIV or RIV. Health care personnel who receive LAIV should avoid providing care for severely immunocompromised persons for 7 days after vaccination.
- The intramuscularly or intradermally administered IIV are options for adults aged 18 through 64 years.
- Adults aged 65 years or older can receive the standard-dose IIV or the highdose IIV (FluZone High-Dose).
- A list of currently available influenza vaccines can be found at www.cdc.gov/flu/protect/vaccine/vaccines.htm.
- Additional information

3. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination

- Administer 1 dose of Tdap vaccine to pregnant women during each pregnancy (preferably during 27 to 36 weeks’ gestation) regardless of interval since prior Td or Tdap vaccination.
- Persons aged 11 years or older who have not received Tdap vaccine or for whom vaccine status is unknown should receive a dose of Tdap followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. Tdap can be administered regardless of interval since the most recent tetanus or diphtheria-toxoid containing vaccine.
- Adults with an unknown or incomplete history of completing a 3-dose primary vaccination series with Td-containing vaccines should begin or complete a primary vaccination series including a Tdap dose.
- For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and the third dose 6 to 12 months after the second.
- For incompletely vaccinated (i.e., less than 3 doses) adults, administer remaining doses.
- Refer to the ACIP statement for recommendations for administering Td/Tdap as prophylaxis in wound management (see footnote 1).

4. Varicella vaccination

- All adults without evidence of immunity to varicella (as defined below) should receive 2 doses of single-antigen varicella vaccine or a second dose if they have received only 1 dose.
- Vaccination should be emphasized for those who have close contact with persons at high risk for severe disease (e.g., health care personnel and family contacts of persons with immunocompromising conditions) or are at high risk for exposure or transmission (e.g., teachers; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; nonpregnant women of childbearing age; and international travelers).
- Pregnant women should be assessed for evidence of varicella immunity. Women who do not have evidence of immunity should receive the first dose of varicella vaccine upon completion or termination of pregnancy and before discharge from the health care facility. The second dose should be administered 4 to 8 weeks after the first dose.
- Evidence of immunity to varicella in adults includes any of the following:
  - documentation of 2 doses of varicella vaccine at least 4 weeks apart.
  - history of varicella based on diagnosis or verification of varicella disease by a health care provider.
  - history of herpes zoster based on diagnosis or verification of herpes zoster disease by a health care provider.
  - laboratory evidence of immunity or laboratory confirmation of disease.

5. Human papillomavirus (HPV) vaccination

- Two vaccines are licensed for use in females, bivalent HPV vaccine (HPV2) and quadrivalent HPV vaccine (HPV4), and one HPV vaccine for use in males (HPV4).
- For females, either HPV4 or HPV2 is recommended in a 3-dose series for routine vaccination at age 11 or 12 years and for those aged 13 through 26 years, if not previously vaccinated.
- For males, HPV4 is recommended in a 3-dose series for routine vaccination at age 11 or 12 years and for those aged 13 through 21 years, if not previously vaccinated. Males aged 22 through 26 years may be vaccinated.
- HPV4 is recommended for men who have sex with men through age 26 years for those who did not get any or all doses when they were younger.
- Vaccination is recommended for immunocompromised persons (including those with HIV infection) through age 26 years for those who did not get any or all doses when they were younger.
- A complete series for either HPV4 or HPV2 consists of 3 doses. The second dose should be administered 4 to 8 weeks (minimum interval of 4 weeks) after the first dose; the third dose should be administered 24 weeks after the first dose and 16 weeks after the second dose (minimum interval of at least 12 weeks).
- HPV vaccines are not recommended for use in pregnant women. However, pregnancy testing is not needed before vaccination. If a woman is found to be pregnant after initiating the vaccination series, no intervention is needed; the remainder of the 3-dose series should be delayed until completion or termination of pregnancy.

6. Zoster vaccination

- A single dose of zoster vaccine is recommended for adults aged 60 years or older regardless of whether they report a prior episode of herpes zoster. Although the vaccine is licensed by the U.S. Food and Drug Administration for use among and can be administered to persons aged 50 years or older, ACIP recommends that vaccination begin at age 60 years.

7. Measles, mumps, rubella (MMR) vaccination

- Persons vaccinated before 1978 with either killed mumps vaccine or mumps vaccine of unknown type who are at high risk for mumps infection (e.g., persons who are working in a health care facility) should be considered for revaccination with 2 doses of MMR vaccine.
- Measles component:
  - A routine second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for adults who:
    - are students in postsecondary educational institutions,
    - work in a health care facility, or
    - plan to travel internationally.
- Rubella component:
  - For women of childbearing age, regardless of birth year, rubella immunity should be determined. If there is no evidence of immunity, women who are not pregnant should be vaccinated. Pregnant women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the health care facility. Health care personnel born before 1957.
  - For unvaccinated health care personnel born before 1957 who lack laboratory evidence of immunity, measles, mumps, and/or rubella immunity or laboratory confirmation of disease, health care facilities should consider vaccinating personnel with 2 doses of MMR vaccine at the appropriate interval for measles and mumps or 1 dose of MMR vaccine for rubella.

8. Pneumococcal vaccine

- Pneumococcal vaccine is indicated for adults 50 years or older who:
  - have not received PCV13 or PPSV23; Administer PCV13 followed by PPSV23 in 6 to 12 months.
  - have not received PCV13 and PPSV23 are indicated, PCV13 should be administered first; PCV13 and PPSV23 should not be administered during the same visit.
  - have not received PCV13 and PPSV23 should be administered to adults whose pneumococcal vaccination history is incomplete or unknown.
- Adults aged 65 years or older who:
  - have not received PCV13 or PPSV23; Administer PCV13 followed by PPSV23 in 6 to 12 months.
  - have not received PCV13 but have received a dose of PPSV23 at age 65 years or older:
    - Administer PCV13 at least 1 year after the dose of PPSV23 received at age 65 years or older.
  - have not received PCV13 but have received 1 or more doses of PPSV23 before age 65:
    - Administer PCV13 at least 1 year after the most recent dose of PPSV23; administer a dose
Figure 6. Footnotes—Immunization Schedule for Adults 19 Years and Older—United States, 2015. (Cont’d)

of PPSV23 to 6 months after PCV13, or as soon as possible if this time window has passed, and at least 5 years after the most recent dose of PPSV23.

— Have received PCV13 but not PPSV23 before age 65 years: Administer PPSV23 6 to 12 months after PCV13 or as soon as possible if this time window has passed.

— Have received PCV13 and 1 or more doses of PPSV23 before age 65 years: Administer PPSV23 6 to 12 months after PCV13, or as soon as possible if this time window has passed, and at least 5 years after the most recent dose of PPSV23.

• Adults aged 19 through 64 years with immunocompromising conditions or anatomical or functional asplenia (defined below) who

— Have not received PCV13 or PPSV23: Administer PCV13 followed by PPSV23 at least 8 weeks after PCV13; administer a second dose of PPSV23 at least 5 years after the first dose of PPSV23.

— Have not received PCV13 but have received 1 dose of PPSV23: Administer PCV13 at least 1 year after the PPSV23; administer a second dose of PPSV23 at least 8 weeks after PCV13 and at least 5 years after the first dose of PPSV23.

— Have not received PCV13 but have received 2 doses of PPSV23: Administer PCV13 at least 1 year after the most recent dose of PPSV23.

— Have received PCV13 but not PPSV23: Administer PPSV23 at least 8 weeks after PCV13; administer a second dose of PPSV23 at least 5 years after the first dose of PPSV23.

— Have received PCV13 and 1 dose of PPSV23: Administer a second dose of PPSV23 at least 5 years after the first dose of PPSV23.

• Adults aged 19 through 64 years with cerebrospinal fluid leaks or cochlear implants: Administer PCV13 followed by PPSV23 at least 8 weeks after PCV13.

• Adults aged 19 through 64 years with chronic heart disease (including congestive heart failure and cardiomyopathies, excluding hypertension), chronic lung disease (including chronic obstructive lung disease, emphysema, and asthma), chronic liver disease (including cirrhosis), alcoholism, or diabetes mellitus: Administer PPSV23.

• Adults aged 19 through 64 years who smoke cigarettes or reside in nursing home or long-term care facilities: Administer PPSV23.

• Routine pneumococcal vaccination is not recommended for American Indian/Alaska Native or other adults unless they have the indications as above; however, public health authorities may consider recommending the use of pneumococcal vaccines for American Indians/Alaska Natives or other adults who live in areas with increased risk for invasive pneumococcal disease.

• Immunocompromising conditions that are indications for pneumococcal vaccination are: Congenital or acquired immunodeficiency (including B- or T-lymphocyte deficiency, complement deficiencies, and phagocytic disorders excluding chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, Hodgkin disease, generalized malignancy, multiple myeloma, solid organ transplant, and iatrogenic immunosuppression (including long-term systemic corticosteroids and radiation therapy).

• Anatomical or functional asplenia that are indications for pneumococcal vaccination are: Sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, splenic dysfunction, and splenectomy. Administer pneumococcal vaccines at least 2 weeks before immunosuppressive therapy or an elective splenectomy, and as soon as possible to adults who are newly diagnosed with asymptomatic or symptomatic HIV infection.

9. Meningococcal vaccination

• Administer 2 doses of quadrivalent meningoococcal conjugate vaccine (MenACWY [Menactra, Menveo]) at least 2 months apart to adults of all ages with anatomical or functional asplenia or persistent complement component deficiencies. HIV infection is not an indication for routine vaccination with MenACWY. If an HIV-infected person of any age is vaccinated, 2 doses of MenACWY should be administered at least 2 months apart.

• Administer a single dose of meningococcal vaccine to microbiologists routinely exposed to isolates of Neisseria meningitidis, military recruits, persons at risk during an outbreak attributable to a vaccine serogroup, and persons who travel to or live in countries in which meningococcal disease is hyperendemic or epidemic.

• First-year college students up through age 21 years who are living in residence halls should be vaccinated if they have not received a dose on or after their 16th birthday.

• MenACWY is preferred for adults with any of the preceding indications who are aged 55 years or younger as well as for adults aged 56 years or older who

a) were vaccinated previously with MenACWY and are recommended for revaccination, or
b) for whom multiple doses are anticipated. Meningococcal polysaccharide vaccine (MPSV4 [Menomune]) is preferred for adults aged 56 years or older who have not received MenACWY previously and who require a single dose only (e.g., travelers).

• Revaccination with MenACWY every 5 years is recommended for adults previously vaccinated with MenACWY or MPSV4 who remain at increased risk for infection (e.g., adults with anatomical or functional asplenia, persistent complement component deficiencies, or microbiologists).

10. Hepatitis A vaccination

• Vaccine anyone seeking protection from hepatitis A virus (HAV) infection and persons with any of the following indications:

— men who have sex with men and persons who use injection or noninjection illicit drugs;
— persons working with HAV-infected primate or with HAV in a research laboratory setting;
— persons with chronic liver disease and persons who receive clotting factor concentrates;
— persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A; and
— unvaccinated persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high intermediate endemicity. (See footnote 1 for more information on travel recommendations.) The first dose of the 2-dose hepatitis A vaccine series should be administered as soon as adoption is planned, ideally 2 or more weeks before the arrival of the adoptee.

• Single-antigen vaccine formulations should be administered in a 2-dose schedule at either 0 and 6 to 12 months (Havrix), or 0 and 6 to 18 months (Vaqta). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, administer 3 doses at 0, 1, and 6 months; alternatively, a 4-dose schedule may be used, administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12.

11. Hepatitis B vaccination

• Vaccinate persons with any of the following indications and any person seeking protection from hepatitis B virus (HBV) infection:

— sexually active persons who are not in a long-term, mutually monogamous relationship (e.g., persons with more than 1 sex partner during the previous 6 months); persons seeking evaluation or treatment for a sexually transmitted disease (STD); current or recent injection drug users; and men who have sex with men;
— health care personnel and public safety workers who are potentially exposed to blood or other infectious body fluids;
— persons with diabetes who are younger than age 60 years as soon as feasible after diagnosis; persons with diabetes who are age 60 years or older at the discretion of the treating clinician based on the likelihood of acquiring HBV infection, including the risk posed by an increased need for assisted blood glucose monitoring in long-term care facilities, the likelihood of experiencing chronic sequelae if infected with HBV, and the likelihood of immune response to vaccination;
— persons with end-stage renal disease, including patients receiving hemodialysis, persons with HIV infection, and persons with chronic liver disease;
— HIV-infected contacts and sex partners of hepatitis B surface antigen–positive persons, clients and staff members of institutions for persons with developmental disabilities, and international travelers to countries with high or intermediate prevalence of chronic HBV infection; and
— all adults in the following settings: STD treatment facilities, HIV testing and treatment facilities, facilities providing drug abuse treatment and prevention services, health care settings targeting services to injection drug users or men who have sex with men, correctional facilities, end-stage renal disease programs and facilities for chronic hemodialysis patients, and institutions and nonresidential day care facilities for persons with developmental disabilities.

• Administer missing doses to complete a 3-dose series of hepatitis B vaccine to those persons not vaccinated or not completely vaccinated. The second dose should be administered 1 month after the first dose; the third dose should be given at least 2 months after the second dose (and at least 4 months after the first dose). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, give 3 doses at 0, 1, and 6 months; alternatively, a 4-dose Twinrix schedule, administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12 may be used.

• Adult patients receiving hemodialysis or with other immunocompromising conditions should receive 1 dose of 40 mcg/mL Recombivax HB administered on a 3-dose schedule at 0, 1, and 6 months or 2 doses of 20 mcg/mL Engerix-B administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months.

12. Haemophilus influenzae type b (Hib) vaccination

• One dose of Hib vaccine should be administered to persons who have anatomiocutaneous or functional asplenia or sickle cell disease or are undergoing elective splenectomy if they have not previously received Hib vaccine. Hib vaccination 14 or more days before splenectomy is suggested.

• Recipients of a hematopoietic stem cell transplant (HSCT) should be vaccinated with a 3-dose regimen 6 to 12 months after a successful transplant, regardless of vaccination history; at least 4 weeks should separate doses.

• Hib vaccine is not recommended for adults with HIV infection since their risk for Hib infection is low.

13. Immunocompromising conditions

• Inactivated vaccines generally are acceptable (e.g., pneumococcal, meningococcal, and inactivated influenza vaccine) and live vaccines generally are avoided in persons with immune deficiencies or immunocompromising conditions. Information on specific conditions is available at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Contraindications</th>
<th>Precautions</th>
</tr>
</thead>
</table>
| Influenza, inactivated (IIV)<sup>1</sup> | • Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine or to a vaccine component, including egg protein | • Moderate or severe acute illness with or without fever  
• History of Guillain-Barré Syndrome within 6 weeks of previous influenza vaccination  
• Adults who experience only hives with exposure to eggs may receive RIV or, with additional safety precautions, IIV<sup>2</sup> |
| Influenza, recombinant (RIV) | • Severe allergic reaction (e.g., anaphylaxis) after previous dose of RIV or to a vaccine component. RIV does not contain any egg protein<sup>2</sup> | • Moderate or severe acute illness with or without fever  
• History of Guillain-Barré Syndrome within 6 weeks of previous influenza vaccination |
| Influenza, live attenuated (LAIV)<sup>1</sup> | • Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, or to a previous dose of any influenza vaccine  
• In addition, ACIP recommends that LAIV not be used in the following populations:  
  - pregnant women  
  - immunosuppressed adults  
  - adults with egg allergy of any severity  
  - adults who have taken influenza antiviral medications (amantadine, rimantadine, zanamivir, or oseltamivir) within the previous 48 hours; avoid use of these antiviral drugs for 14 days after vaccination | • Moderate or severe acute illness with or without fever  
• History of Guillain-Barré Syndrome within 6 weeks of previous influenza vaccination  
• Asthma in persons aged 5 years and older  
• Other chronic medical conditions, e.g., other chronic lung diseases, chronic cardiovascular disease (including isolated hypertension), diabetes, chronic renal or hepatic disease, hematologic disease, neurologic disease, and metabolic disorders |
| Pneumococcal conjugate (PCV13) | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component  
• For pertussis-containing vaccines: encephalopathy (e.g., coma, decreased level of consciousness, or prolonged seizures) not attributable to another identifiable cause within 7 days of administration of a previous dose of TDap, diphtheria and tetanus toxoids and pertussis (DTP), or diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine | • Moderate or severe acute illness with or without fever |
| Varicella<sup>4</sup> | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component  
• Known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy) or patients with human immunodeficiency virus (HIV) infection who are severely immunocompromised  
• Pregnancy | • Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product)<sup>1</sup>  
• Moderate or severe acute illness with or without fever  
• Receipt of specific antivirals (i.e., acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; avoid use of these antiviral drugs for 14 days after vaccination |
| Human papillomavirus (HPV) | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component | • Moderate or severe acute illness with or without fever |
| Zoster<sup>4</sup> | • Severe allergic reaction (e.g., anaphylaxis) to a vaccine component  
• Known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, or long-term immunosuppressive therapy) or patients with HIV infection who are severely immunocompromised  
• Pregnancy | • Moderate or severe acute illness with or without fever  
• Receipt of specific antivirals (i.e., acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; avoid use of these antiviral drugs for 14 days after vaccination |
| Measles, mumps, rubella (MMR)<sup>2</sup> | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component, including to any vaccine containing diphtheria toxoid  
• Known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy) or patients with HIV infection who are severely immunocompromised  
• Pregnancy | • Moderate or severe acute illness with or without fever  
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product)<sup>1</sup>  
• History of thrombocytopenia or thrombocytopenic purpura  
• Need for tuberculin skin testing<sup>6</sup> |
| Pneumococcal polysaccharide (PPV23) | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component | • Moderate or severe acute illness with or without fever |
| Meningococcal, conjugate (MenACWY); meningococcal, polysaccharide (MPSV4) | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component | • Moderate or severe acute illness with or without fever |
| Hepatitis A | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component | • Moderate or severe acute illness with or without fever |
| Hepatitis B | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component | • Moderate or severe acute illness with or without fever |
| Haemophilus influenzae Type b (Hib) | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component | • Moderate or severe acute illness with or without fever |

1. Vaccine package inserts and the full ACP recommendations for these vaccines should be consulted for additional information on vaccine-related contraindications and precautions and for more information on vaccine recipients. Events or conditions listed as precautions should be reviewed carefully. Benefits of and risks for administering a specific vaccine to a person under these circumstances should be considered. If the risk from the vaccine is too great, it may not be administered. If the benefit of vaccination is believed to outweigh the risk, the vaccine should be administered. A contraindication is a condition in a recipient that increases the chance of a serious adverse reaction. Therefore, a vaccine should not be administered when a contraindication is present.

2. For more information on use of influenza vaccines among persons with egg allergies and a complete list of conditions that CDC considers to be reasons to avoid receiving LAIV, see CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2014–15 Influenza Season. MMWR 2014;63(3):691–97.

3. LAIV, MMR, varicella, or zoster vaccines can be administered on the same day. If not administered on the same day, live vaccines should be separated by at least 28 days.

4. Immunosuppressive steroid dose is considered to be >2 weeks of daily receipt of 20 mg of prednisone or the equivalent. Vaccination should be deferred for at least 1 month after discontinuation of such therapy.

5. Vaccine should be deferred for the appropriate interval if replacement immune globulin products are being administered. See CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(RR-2). Available at www.cdc.gov/vaccines/pubs/pinkbook/index.html.

6. Measles vaccination may suppress tuberculin reactivity temporarily. Measles-containing vaccine may be administered on the same day as tuberculin skin testing. If testing cannot be performed until after the day of MMR vaccination, the test should be postponed for at least 4 weeks after the vaccination. If an urgent need exists to skin test, do so with the understanding that reactivity might be reduced by the vaccine.


8. Regarding latex allergy, consult the package insert for any vaccine administered.
New Report Available

Recent Birth Trends in Los Angeles County

This report highlights changing trends in births, factors contributing to these changes, and potential public health impacts. This report is a valuable tool in the planning of public services and for those interested in public health impact and policy considerations of present and future birth trends in the County.

Highlights of the report include:

- The annual number of births in LA County has decreased dramatically – from over 204,000 in 1990 to just over 130,300 births in 2011.
- Steepest declines in birth rates were seen among teen mothers (-59%) and young women under the age of 25 (-49%).
- During the same period, birth rates increased for women aged 25-34 years (+11%) and women aged 40-44 years (+33%) – increasing the potential for negative health impacts to both mother and baby associated with older maternal age.

To view the full report online, visit

http://publichealth.lacounty.gov/epi/

Index of Disease Reporting Forms

All case reporting forms from the LA County Department of Public Health are available by telephone or Internet.

Reportable Diseases & Conditions
Confidential Morbidity Report
Morbidity Unit (888) 397-3993
Acute Communicable Disease Control (213) 240-7941

Sexually Transmitted Disease
Confidential Morbidity Report
(213) 744-3070

Adult HIV/AIDS Case Report Form
For patients over 13 years of age at time of diagnosis
Division of HIV and STD Programs (213) 351-8196
www.publichealth.lacounty.gov/dhsp/ReportCase.htm

Pediatric HIV/AIDS Case Report Form
For patients less than 13 years of age at time of diagnosis
Pediatric AIDS Surveillance Program (213) 351-8153
Must first call program before reporting
www.publichealth.lacounty.gov/dhsp/ReportCase.htm

Tuberculosis Suspects & Cases
Confidential Morbidity Report
Tuberculosis Control (213) 745-0800
www.publichealth.lacounty.gov/tb/forms/cmr.pdf

Lead Reporting
No reporting form. Reports are taken over the phone.
Lead Program (323) 869-7195

Animal Bite Report Form
Veterinary Public Health (877) 747-2243
www.publichealth.lacounty.gov/vet/biteintro.htm

Animal Diseases and Syndrome
Report Form
Veterinary Public Health (877) 747-2243
www.publichealth.lacounty.gov/vet/disintro.htm

Use of trade names and commercial sources in Rx for Prevention is for identification only and does not imply endorsement by the Los Angeles County Department of Public Health (LACDPH). References to non-LACDPH sites on the Internet are provided as a service to Rx for Prevention readers and do not constitute or imply endorsement of these organizations or their programs by LACDPH. The Los Angeles County Department of Public Health is not responsible for the content of these sites. URL addresses listed in Rx for Prevention were current as of the date of publication.